JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 15, 2026, 15:57Early Bird Registration Opens for RCOG Female Reproductive Physiology Course – RCOG
-
Jul 15, 2026, 15:53ACOG Joins Coalition to Advance National Women’s Health Strategy – ACOG
-
Jul 15, 2026, 15:44From the Shadow of Pregnancy Loss to a New Pregnancy – RBMO
-
Jul 15, 2026, 15:27Supporting the Launch of the National Strategy to Close the Women’s Health Gap – ASRM
-
Jul 15, 2026, 15:21Sergio Haimovich: AI Is Already Reshaping Scientific Publishing and Disclosure Is Lagging Behind
-
Jul 15, 2026, 15:12The Egg’s Engine Is Fed Plenty of Fuel, It Just Can’t Burn It – Fertility Plus
-
Jul 15, 2026, 15:07Join the Ultrasound in Obstetrics and Gynecology Team as the UOG Social Media Editor – ISUOG
-
Jul 15, 2026, 14:56Can Ultrasound Reliably Detect Residual Cervical Cancer After Conization? – IJGC
-
Jul 15, 2026, 14:27Marco Zaccaria: A Great Webinar, Hosted By BSGE and BMUS